Introduction
============

Cardiovascular diseases are the leading cause of death, accounting for approximately 30% of all deaths worldwide \[[@B1]\]. Among the various cardiovascular diseases, acute myocardial infarction (AMI) has a high rate of mortality, and infarct size is a primary determinant of prognosis in these patients. The only established and clinically approved method to limit infarct size is restoration of coronary blood flow by percutaneous coronary interventions (PCI), thrombolytic agents or coronary bypass surgery. However, our recent review of clinical infarct size data indicated that infarct size after current reperfusion therapy was larger than 75% of the area at risk and larger than 20% of the left ventricle in one fourth of AMI patients \[[@B2]\]. Lack of substantial myocardial salvage in those patients cannot be simply attributable to long symptom-to-reperfusion time, and involvement of reperfusion injury \[[@B3]\] is also possible. Nevertheless, significant percentages of AMI patients suffer from insufficient cardiac function and have a poor prognosis even after successful restoration of coronary flow \[[@B2]\]. Therefore, the establishment of a novel strategy to limit the extent of infarction during ischemia/reperfusion is of great clinical importance.

As a cardioprotective strategy, ischemic preconditioning (PC) has received much attention for its potent infarct size-limiting effect since its first report by Murry et al. in 1986 \[[@B4]\]. Zhao et al. found that "conditioning" with repetitive ischemia/reperfusion at the time of reperfusion also affords protection and named the phenomenon ischemic postconditioning (PostC) \[[@B5]\]. Laboratory investigations to date have clarified outlines of the intracellular mechanisms of PC and PostC \[[@B6]-[@B9]\]. In addition, several agents targeting signaling relevant to PC and PostC have been shown to act as PostC mimetics \[[@B6]-[@B8]\]. However, clinical benefits of PC, PostC and their mimetics were not always demonstrated in clinical trials \[[@B8],[@B10]\]. The discrepancy between results of animal studies and clinical trials may be explained by notable differences between animal models of AMI and AMI in humans \[[@B2],[@B10]\]. First, there are species differences in regulatory mechanisms of cardiomyocytes such as contribution of sarcolemmal Ca^2+^ ATPase to overall Ca^2+^ handling. Second, the timing of administration of the test agent was not exactly the same in the positive animal studies and negative clinical trials. Third, most of the patients with AMI were pretreated with pharmacological agents for their co-morbidities at the onset of AMI, whereas animals were untreated, except for anesthetic agents, before AMI in most of the previous studies. Pharmacological agents used for treatment of hypertension, dyslipidemia and/or diabetes mellitus (DM) potentially modify intracellular signaling relevant to cytoprotection and thus myocardial responses to PC, Post and PC mimetics. Fourth, AMI patients recruited to clinical studies were generally old and had concomitant diseases, whereas relatively young and healthy animals were used in most of the previous animal studies. Aging and co-morbidities have been shown to modify or even abrogate the infarct size-limiting effects of interventions in animal experiments \[[@B6],[@B11]\] and thus possibly underlie the negative results in clinical trials.

Of morbidities that potentially compromise the protective mechanisms of the heart, DM appears primarily important to study today. The number of patients with DM has been increasing worldwide in the past two decades, and these patients are predisposed to serious cardiovascular morbidity and mortality \[[@B12]\]. Despite recent progress in coronary intervention strategies, DM is associated with higher mortality after AMI due to more extensive atherosclerotic lesions and also hypertrophied and dysfunctional left ventricle \[[@B13]-[@B15]\]. Interestingly, Lamblin et al. recently showed that rates of cardiovascular death and heart failure after the first AMI were higher in DM patients than in non-DM patients, though ventricular function and remodeling were comparable in the two groups \[[@B16]\]. The increased mortality after AMI in DM patients is unlikely to be prevented simply by improvement of glycemic control, since intensive glycemic controls failed to reduce cardiovascular events as well as mortality rate in DM patients in recent large-scale clinical trials \[[@B17]-[@B19]\]. Hence, we need novel strategies for protecting DM patients with coronary artery diseases from excessive myocardial ischemia-reperfusion injury. To gain an insight into a novel strategy, we thoroughly review reported effects of DM on myocardial infarct size and on protective mechanisms against infarction and discuss future perspectives in this article. Our discussion on pathophysiology and clinical approach to diabetic cardiomyopathy was recently published elsewhere \[[@B20]\].

Changes in myocardial susceptibility to infarction by DM
========================================================

Clinical studies showed that DM increased the susceptibility of the myocardium to ischemia/reperfusion injury \[[@B21],[@B22]\]. However, results of infarct size studies in diabetic animal models were contradictory (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}), and the reason for the inconsistency remains unclear.

###### 

Effect of diabetes mellitus on infarct size

  **Species**                      **DM**                   **Index ischemia**                    **First author**   **Journal**
  ------------------------------- -------- --------------- -------------------- ----------------- ------------------ -----------------------------------
  **Infarct size enlargement**                                                                                       
  Dog                                2     75 d                    120          regional, vivo    Forrat             Cardiovasc Res 1993
  Rat (SD)                           1     8 d                      25          regional, vivo    Marfella           Diabetologia 2002
  Rat (SD)                           1     8 d                      25          regional, vivo    Di Filippo         Diabetes 2005
  Rat (SD)                           1     30 d                     30          global, vitro     Thirunavukkarasu   Free Radic Biol Med 2007
  Rat (Wistar)                       1     2 w                      30          regional, vivo    Xiao               J Pharmacol Exp Ther 2004
  Rat (Zucker obese)                 2                              30          regional, vivo    Jordan             J Pharmacol Exp Ther 2003
  Rat (Zucker obese)                 2     (10-12 w old)            30          regional, vivo    Katakam            Am J Physiol 2007
  Rat (Zucker diabetic fatty)        2     (10-12 w old)            30          regional, vivo    Yue                Diabetes 2005
  Rat (Zucker diabetic fatty)        2     (12-16 w old)            30          regional, vivo    La Bonte           Am J Physiol 2008
  Rat (OLETF)                        2     (25-30 w old)            20          regional, vivo    Miki               Diabetes 2009
  Rat (OLETF)                        2     (25-30 w old)            20          regional, vivo    Hotta              Circ Res 2010
  Mice                               1     8 d                      25          regional, vivo    Marfella           Diabetes 2004
  Mice                               1     4 w                      60          regional, vivo    Liu                Diabetes 2005
  Mice (ob/ob)                       2     (8-10 w old)             30          regional, vivo    Bouhidel           Am J Physiol 2008
  Mice (ob/ob)                       2     (8-10 w old)             30          regional, vivo    Calvert            Diabetes 2008
  Mice (ob/ob)                       2     (10-12 w old)            30          regional, vivo    Zhu                J Cell Mol Med 2011
  Mice (KK-Ay)                       2     (6 w old)                40          regional, vivo    Honda              J Mol Cell Cardiol 2008
  **Infarct size reduction**                                                                                         
  Rabbit (NZ)                        1     8 w                      30          regional, vivo    Hadour             J Mol Cell Cardiol 1998
  Rat (SD)                           1     2 w                      30          regional, vivo    Ma                 N-S Arch Pharmacol 2006
  Rat (Wistar)                       2     11-12 m                30, 45        regional, vivo    Liu                Circulation 1993
  Rat (Wistar)                       1     1 w                      30          regional, vivo    Ravingerová        Mol Cell Biochem 2003
  Rat (Wistar)                       1     4 w                      30          regional, vivo    Xu                 Exp Mol Pathol 2004
  Rat (Wistar)                       1     6 w                      30          regional, vivo    Galagudza          Neurosci Behav Physiol 2007
  Rat (Wistar)                       2     10-12 w                  30          global, vitro     Kravchuk           Exp Diabetes Res 2011
  Rat (Wistar-Kyoto)                 2     9 m                      40          regional, vitro   Mozaffari          Hypertension 2003
  Rat (Zucker diabetic fatty)        2     (16 w old)               50          regional, vitro   Kristiansen        Diabetologia 2004
  Rat (Goto-Kakizaki)                2     (16 w old)               50          regional, vitro   Kristiansen        Diabetologia 2004
  Rat (Goto-Kakizaki)                2     (16 w old)               45          regional, vitro   Kristiansen        Diabetologia 2011
  **No change in infarct size**                                                                                      
  Dog                                1     3 w                      60          regional, vivo    Kersten            Am J Physiol 2000
  Dog                                1     3 w                      60          regional, vivo    Kersten            Am J Physiol 2001
  Rabbit (NZ)                        1     10-16 w                  30          regional, vivo    Vogel              Circ Res 1988
  Rabbit (NZ)                        1     4-5 w                    60          regional, vivo    Nieszner           Exp Clin Endocrinol Diabetes 2002
  Rabbit (NZ white)                  1     5-6 w                    30          regional, vivo    Ebel               Pflügers Arch 2003
  Rat (SD)                           1     6 w                      30          regional, vivo    Ma                 N-S Arch Pharmacol 2006
  Rat (SD)                           1     2 w                      30          regional, vivo    Gross              Diabetes 2007
  Rat (SD)                           1     4 w, 8 w                 30          global, vitro     Shi-Ting           Biomed Pharmacother 2010
  Rat (SD)                           1     4-5 w                    30          regional, vivo    Drenger            Anesthesiology 2011
  Rat (SD)                           1     4 w                      30          global, vitro     Okazaki            J Mol Cell Cardiol 2011
  Rat (Wistar)                       1     8 w                      30          regional, vitro   Joyeux             Cardiovasc Res 1999
  Rat (Wistar)                       1     8 w                      30          regional, vivo    Ravingerová        Mol Cell Biochem 2003
  Rat (Wistar)                       1     20 w                     30          regional, vivo    Xu                 Exp Mol Pathol 2004
  Rat (Wistar)                       1     4 w                      25          global, vitro     Ghaboura           Basic Res Cardiol 2011
  Rat (Goto-Kakizaki)                2                              35          regional, vitro   Tsang              Diabetes 2005
  Rat (Goto-Kakizaki)                2                              35          regional, vitro   Bhamra             Basic Res Cardiol 2008
  Rat (Goto-Kakizaki)                2     (12 w old)               35          regional, vivo    Bulhak             Am J Physiol 2009
  Rat (Goto-Kakizaki)                2                              30          regional, vivo    Matsumoto          Cardiovasc Drug Ther 2009
  Mice                               1     2 w                      30          global, vitro     Przyklenk          Antioxid Redox Signal 2011
  Mice (ob/ob)                       2     (12-14 w old)            30          global, vitro     Przyklenk          Antioxid Redox Signal 2011

SD, Sprague--Dawley; NZ, New Zealand; OLETF, Otsuka Long-Evans-Tokushima fatty; d, days; w, weeks.

###### 

Effect of hyperglycemia on infarct size

  **Species**                     **Duration of hyperglycemia**   **Blood sugar (mg/dl)**    **Index ischemia**                    **First author**   **Journal**
  ------------------------------- ------------------------------- ------------------------- -------------------- ----------------- ------------------ -------------------------------
  **Hyperglycemia**                                                                                                                                   
  **Infarct size enlargement**                                                                                                                        
  Dog                             before I                        585 vs. 71                         60          regional, vivo    Kersten            Am J Physiol 1998
  Rabbit (NZ white)               throughout                      594 vs. 99                         30          regional, vitro   Wong               J Diabetes Complications 2011
  Rat (SD)                        during I                        324 vs 85                          30          regional, vivo    Su                 Am J Physiol 2007
  **No change in infarct size**                                                                                                                       
  Dog                             before I                        310 vs. 71                         60          regional, vivo    Kersten            Am J Physiol 1998
  Dog                             before I                        310 vs. 75                         60          regional, vivo    Kersten            Am J Physiol 2001
  Dog                             before I                        316, 579 vs. 78                    60          regional, vivo    Kehl               Anesthesiology 2002
  Dog                             before I                        307 vs 83                          60          regional, vivo    Gu                 Anesthesiology 2008
  Rabbit (NZ white)               before and during I             660 vs. 185                        30          regional, vivo    Ebel               Pflugers Arch 2003
  Rabbit (NZ white)               before I                        257 vs 124                         30          regional, vivo    Amour              Anesthesiology 2010
  Rabbit (NZ white)               before and during I             338 vs 142                         40          regional, vivo    Raphael            J Cardiovasc Pharmacol 2010
  Rat (SD)                        before and during I             360 vs 112                         30          regional, vivo    Ichinomiya         Cardiovasc Diabetol 2012
  Rat (Wistar)                    before and during I             \>400 vs. 121                      25          regional, vivo    Weber              Eur J Pharmacol 2008
  Rat (Wistar)                    before and during I             459 vs 128                         25          regional, vivo    Huhn               Br J Anaesth 2008
  Rat (Wistar)                    before and during I             355 vs 89                          30          regional, vivo    Matsumoto          Cardiovasc Diabetol 2012
  **Metabolic syndrome**                                                                                                                              
  **Infarct size enlargement**                                                                                                                        
  Rat (Wistar)                    Western diet for 16 w           95 vs 87                           40          regional, vitro   du Toit            Am J Physiol 2008
  **No change in infarct size**                                                                                                                       
  Rat (SD)                        high fat diet for 13 w          160 vs 144                         45          regional, vivo    Thim               Clin Sci (Lond) 2006
  Rat (WOKW)                      (28 w old)                      105 vs. ?                          30          regional, vivo    Wagner             J Cardiovasc Pharmacol 2008

*NZ* New Zealand, *SD* Sprague--Dawley, *WOKW* Wistar-Ottawa-Karlsburg W, *before I* before ischemia, *during I* during ischemia, *w* weeks.

Multiple mechanisms are involved in cardiomyocyte necrosis induced by ischemia/reperfusion. Depletion of intracellular ATP, intracellular overloading with Na^+^ and Ca^2+^, and increased fragility of the cell membrane are major changes during ischemia relevant to cell necrosis. Accumulating evidence supports the notion that the mitochondrial permeability transition pore (mPTP) is primed during ischemia and is opened by Ca^2+^ overload and burst of reactive oxygen species at the time of reperfusion, leading to irreversible loss of mitochondrial functions and cell necrosis \[[@B23]\]. Theoretically, modification of ischemia-induced changes or reperfusion-induced opening of the mPTP should underlie the change in myocardial susceptibility to infarction in DM hearts. However, such modification has not been understood well.

Experimental studies
--------------------

Infarct size in animal models of DM was larger or smaller than or similar to, depending on reports, that in non-diabetic controls (Table [1](#T1){ref-type="table"}). As shown in Table [1](#T1){ref-type="table"}, there were numerous differences in experimental preparations and protocols, and a single factor cannot entirely explain the discrepancy in the effects of DM on infarct size. Duration of the diabetic state and plasma level of insulin (i.e., type 1 DM vs. type 2 DM) appear to influence myocardial tolerance against infarction. In a study by Ravingerová et al. \[[@B24]\], infarct size after 30-min ischemia was smaller in diabetic rat hearts at 1 week after streptozotocin (STZ) injection than in controls, but this infarct size limitation was not detected 8 weeks later. Two other studies have also shown that resistance of diabetic hearts to ischemia/reperfusion injury was detectable at the early phase of DM and disappeared later \[[@B25],[@B26]\]. However, enlargement of infarct size was observed as early as 8 days after STZ injection \[[@B27]-[@B29]\], indicating that duration of DM is not the only factor responsible for inconsistent effects of DM on infarct size.

Difference in metabolic profiles associated with DM (i.e., presence or absence of hyperinsulinemia and types of dyslipidemia) may also be responsible for different changes in infarct size in DM animals. With a few exceptions \[[@B30],[@B31]\], DM models with obesity and hyperinsulinemia showed increased myocardial susceptibility to ischemia/reperfusion-induced necrosis \[[@B32]-[@B41]\]. In contrast, high glucose level induced simply by glucose or dextrose infusion did not affect infarct size in the majority of studies, including two recent studies \[[@B42],[@B43]\] (Table [2](#T2){ref-type="table"}).

Clinical studies
----------------

Increased myocardial susceptibility to infarction in DM patients was indicated by two clinical studies: infarct size determined by SPECT imaging after reperfusion therapy was larger by 30 \~ 70% in DM patients than in non-DM patients \[[@B21],[@B22]\]. The change in myocardial tolerance to infarction is consistent with worse short- and long-term prognosis after AMI in DM patients \[[@B44],[@B45]\]. Of particular relevance, Haffner et al. \[[@B46]\] showed that cardiovascular event risk in DM patients without prior myocardial infarction was comparable to the risk in non-diabetic patients with prior myocardial infarction. However, the untoward effects of DM on prognosis after AMI cannot be explained solely by increased myocardial vulnerability to ischemia/reperfusion injury, since the risk of heart failure and death was significantly higher in DM patients than in non-DM patients with comparable infarct sizes and left ventricular ejection fractions \[[@B47]\]. Myopathic changes ("diabetic cardiomyopathy"), impaired collateral recruitment, microcirculatory abnormalities, and underuse of evidence-based therapies are possible explanations, in addition to increased susceptibility to infarction, for detrimental prognosis after AMI in DM patients.

Defects in intracellular protective signaling in DM hearts
==========================================================

DM is one of the co-morbidities that potentially modify myocardial response to protective interventions, including PC and PostC. A number of studies have been carried out to determine the efficacy of ischemic PC and PostC for protecting the myocardium in animal models of DM (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}) and diabetic patients (Table [5](#T5){ref-type="table"}). The majority of those studies showed that DM interferes with protective mechanisms of cardioprotective interventions. Myocardial protection by PC and PostC is achieved by activation of multiple protective signaling pathways that appear to converge to inhibit mPTP opening upon reperfusion via phosphorylation of glycogen synthase kinase-3β (GSK-3β) at Ser9 \[[@B6],[@B8],[@B9]\], and DM-induced defects in the protective signaling may be different depending on the model and/or phase of DM.

###### 

Effect of diabetes mellitus on cardioprotection by pre- and post-conditioning

  **Species**                    **DM**  **PC stimuli**   **First author**                   **Journal**   
  ----------------------------- -------- ---------------- ---------------------------------- ------------- -----------------------------------
  **Preserved protection**                                                                                 
  **PC**                                                                                                   
  Rat (SD)                         1     4 w              3x 5I5R                            Shi-Ting      Biomed Pharmacother 2010
  Rat (Wistar)                     2     11-12 m          3x 5I5R                            Liu           Circulation 1993
  Rat (Wistar)                     1     6 w              LiCl 20 mM, IND 1 μM, SB 3 μM      Yadav         Mol Cell Biochem 2010
  Rat (Zucker diabetic fatty)      2     (10-12 w old)    Rosiglitazone 3 mg/kg for 1 week   Yue           Diabetes 2005
  Rat (OLETF)                      2     (25-30 w old)    SB 1.2 mg/kg                       Miki          Diabetes 2009
  Rat (Goto-Kakizaki)              2                      3x 5I10R                           Tsang         Diabetes 2005
  Rat (Goto-Kakizaki)              2     (12 w old)       WY 1 mg/kg                         Bulhak        Am J Physiol 2009
  Rat (Goto-Kakizaki)              2                      olprinone 10 μg/kg                 Matsumoto     Cardiovasc Drug Ther 2009
  Mice (ob/ob)                     2     (8-10 w old)     Metformin 125 μg/kg                Calvert       Diabetes 2008
  Mice (KK-A^y^)                   2     (6 w old)        Pioglitazone 25 mg/kg for 2 week   Honda         J Mol Cell Cardiol 2008
  **PostC**                                                                                                 
  Rat (SD)                         1     2 w              SB 0.6 mg/kg                       Gross         Diabetes 2007
  Rat (Wistar)                     1     4 w              SB 3 μM                            Ghaboura      Basic Res Cardiol 2011
  Rat (OLETF)                      2     (25-30 w old)    BIO 0.08 mg/kg                     Hotta         Circ Res 2010
  Rat (Goto-Kakizaki)              2                      Metformin 50 μM                    Bhamra        Basic Res Cardiol 2008
  Mice (ob/ob)                     2     (8-10 w old)     Metformin 125 μg/kg                Calvert       Diabetes 2008
  **Impaired protection**                                                                                  
  **PC**                                                                                                   
  Dog                              1     3 w              4x 5I5R                            Kersten       Am J Physiol 2000
  Dog                              1     3 w              Diazoxide 2.5 mg/kg                Kersten       Am J Physiol 2001
  Rabbit (NZ)                      1     4-5 w            3x 2I2R                            Nieszner      Exp Clin Endocrinol Diabetes 2002
  Rat (SD)                         1     8 w              3x 5I5R                            Wang          Biomedicine Aging Pathol 2011
  Rat (Wistar)                     1     6 w              5I5R                               Galagudza     Neurosci Behav Physiol 2007
  Rat (Wistar)                     1     6 w              4x 5I5R                            Yadav         Mol Cell Biochem 2010
  Rat (Wistar)                     2     10-12 w          Metformin 200 mg/kg for 3 days     Kravchuk      Exp Diabetes Res 2011
  Rat (Zucker obese)               2     (10-12 w old)    5I5R, Diazoxide 10 mg/kg           Katakam       Am J Physiol 2007
  Rat (Zucker diabetic fatty)      2     (16 w old)       4x 2I3R                            Kristiansen   Diabetologia 2004
  Rat (OLETF)                      2     (25-30 w old)    EPO 5000 U/kg                      Miki          Diabetes 2009
  Rat (OLETF)                      2     (25-30 w old)    EPO 5000 U/kg, DADLE 1 mg/kg       Hotta         Circ Res 2010
  Rat (Goto-Kakizaki)              2     (16 w old)       4x 2I3R                            Kristiansen   Diabetologia 2004
  Rat (Goto-Kakizaki)              2                      5I10R, 2x 5I10R                    Tsang         Diabetes 2005
  Rat (Goto-Kakizaki)              2     (16-18 w old)    EPO 5000 U/kg                      Miki          Diabetes 2009
  Rat (Goto-Kakizaki)              2                      isoflurane 1.0%                    Matsumoto     Cardiovasc Drug Ther 2009
  **PostC**                                                                                                
  Rat (SD)                         1     2 w              Morphine 0.3 mg/kg                 Gross         Diabetes 2007
  Rat (SD)                         1     4-5 w            3x 20sR20sI, sevoflurane 1.0 MAC   Drenger       Anesthesiology 2011
  Rat (Wistar)                     1     4 w              Darbopoetin alpha 5 μg/kg          Ghaboura      Basic Res Cardiol 2011
  Mice                             1     2 w              3x 10sR10sI, 6x 10sR10sI           Przyklenk     Antioxid Redox Signal 2011
  Mice (ob/ob)                     2     (8-10 w old)     6x 10sR10sI                        Bouhidel      Am J Physiol 2008
  Mice (ob/ob)                     2     (12-14 w old)    3x 10sR10sI, 6x 10sR10sI           Przyklenk     Antioxid Redox Signal 2011
  Mice (ob/ob)                     2     (10-12 w old)    6x 10sR10sI                        Zhu           J Cell Mol Med 2011
  Mice (KK-A^y^)                   2     (6 w old)        Pioglitazone 25 mg/kg              Honda         J Mol Cell Cardiol 2008
  **Late PC**                                                                                              
  Rabbit (NZ white)                1     5-6 w            5I24hR                             Ebel          Pflugers Arch 2003

*IND* indirubin-3 monooxime (a GSK-3β inhibitor), *SB* SB216763 (a GSK-3β inhibitor), *WY* 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (a PPAR-α agonist), *BIO* 6-bromo-indirubin-3\'-oxime (a GSK3β inhibitor), *EPO* erythropoietin, *DADLE* \[D-Ala2, D-Leu5\]-enkephalin acetate (a δ-opioid receptor agonist), *5I5R* 5-min ischemia/5-min reperfusion, *5I24hR* 5-min ischemia/24-hour reperfusion, *10sR10sI* 10-second reperfusion/10-second ischemia, *MAC* minimal alveolar concentration, *w* weeks, *m* months.

###### 

Effect of hyperglycemia on cardioprotection by pre- and post-conditioning

  **Species**                **Duration of Blood sugar**    **PC stimuli**  **First author**                         **Journal**   
  -------------------------- ----------------------------- ---------------- ---------------------------------------- ------------- -----------------------------
  **Hyperglycemia**                                                                                                                
  **Preserved protection**                                                                                                         
  **PC**                                                                                                                           
  Dog                        before I                            397        Diazoxide 5.0 mg/kg                      Kersten       Am J Physiol 2001
  Dog                        before I                            291        Isoflurane 1.0 MAC                       Kehl          Anesthesiology 2002
  Rat (SD)                   before and during I                 360        Fasudil 0.5 mg/kg                        Ichinomiya    Cardiovasc Diabetol 2012
  Rat (Wistar)               before and during I                 446        Sevoflurane 1.0 MAC + CysA 5 mg/kg       Huhn          Br J Anaesth 2008
  Rat (Wistar)               before and during I               343, 447     MIL 30 μg/kg, LEVO 100 μg/kg             Matsumoto     Cardiovasc Diabetol 2012
  **Impaired protection**                                                                                                          
  **PC**                                                                                                                            
  Dog                        before I                            296        4x 5I5R                                  Kersten       Am J Physiol 1998
  Dog                        before I                            329        Diazoxide 2.5 mg/kg                      Kersten       Am J Physiol 2001
  Dog                        before I                          581, 558     Isoflurane 0.5, 1.0 MAC                  Kehl          Anesthesiology 2002
  Dog                        before I                            293        4x 5I5R                                  Gu            Anesthesiology 2008
  Rabbit (NZ white)          before I                            281        Isoflurane 1.0 MAC                       Amour         Anesthesiology 2010
  Rat (Wistar)               before I or during I               \>400       Desflurane 1.0 MAC                       Weber         Eur J Pharmacol 2008
  **PostC**                                                                                                                         
  Rabbit (NZ white)          before and during I                 353        Isoflurane 1.0 MAC                       Raphael       J Cardiovasc Pharmacol 2010
  Rat (SD)                   before and during I                 360        Diazoxide 10 mg/kg, Fasudil 0.15 mg/kg   Ichinomiya    Cardiovasc Diabetol 2012
  Rat (Wistar)               before and during I               445, 441     Sevoflurane 1.0 MAC, CysA 5 mg/kg        Huhn          Br J Anaesth 2008
  **Metabolic syndrome**                                                                                                           
  **Impaired protection**                                                                                                          
  **PostC**                                                                                                                        
  Rat (WOKW)                 (28 w old)                          105        3x 30sI30sR                              Wagner        J Cardiovasc Pharmacol 2008

*NZ* New Zealand, *SD* Sprague--Dawley, *WOKW* Wistar-Ottawa-Karlsburg W, *before I* before ischemia, *during I* during ischemia, *MAC* minimal alveolar concentration, *CysA* cyclosporine A, *MIL* milrinone, *LEVO* levosimendan, *5I5R* 5-min ischemia/5-min reperfusion, *30sR30sI* 30-second reperfusion/30-second ischemia.

###### 

Effect of ischemic postconditioning in patients with acute myocardial infarction

  **First author**     **% of DM**   **Age**     **Protocol**   **Results**                                             
  -------------------- ------------- ----------- -------------- ------------- ------------------- --------------------- --------------------------
  **Ischemic PostC**                                                                                                    
  Staat                20 vs. 13     58 vs. 56   4x 60sR/I      Improved      N/A                 Reduced (peak, AUC)   N/A
  Laskey               N/A           58 vs. 58   2x 90sR/I      Improved      N/A                 Nochange (peak)       N/A
  Ma                   38 vs. 45     64 vs. 64   3x 30sR/I      N/A           Improved WMSI       Reduced (peak)        N/A
  Yang                 26 vs. 28     59 vs. 63   3x 30sR/I      No change     No change           Reduced (AUC)         Reduced (SPECT, 1w)
  Thibault             12 vs. 10     56 vs. 56   4x 60sR/I      N/A           Improved EF, WMSI   Reduced (AUC)         Reduced (SPECT, 6m)
  Laskey               38 vs. 42     60 vs. 58   2x 90sR/I      Improved      No change           Reduced (peak)        N/A
  Xue                  21 vs. 29     54 vs. 62   4x 60sR/I      Improved      Improved EF, WMSI   Reduced (peak, AUC)   Reduced (SPECT, 1w)
  Lønborg              7 vs. 7       61 vs. 62   4x 30sR/I      No change     No change           N/A                   Reduced (CMR, 3m)
  Sörensson            25 vs. 17     63 vs. 62   4x 60sR/I      N/A           No change \*1       No change (AUC)       No change (CMR, 1w) \*1
  Freixa               23 vs. 17     59 vs. 60   4x 60sR/I      N/A           No change           No change (peak)      No change (CMR, 1w & 6m)
  Tarantini            18 vs. 3      60 vs. 60   4x 60sR/I      No change     No change           No change (AUC)       No change (CMR, 1m)

*DM* diabetes mellitus, *MBG* myocardial blush grade, *CF* coronary flow, *WMSI* wall motion score index, *EF* ejection fraction, *AUC* area under the curve, *MACE* major adverse cardiac events, *SPECT* single photon emission computed tomography, *CMR* cardiovascular magnetic resonance, *w* week, *m* month;

\*1 Improved by postconditioning with large area at risk.

Experimental studies
--------------------

With a few exceptions, previous studies demonstrated that cardioprotection achieved by ischemic PC or PostC is impaired in DM: the infarct size-limiting effect was lost or required extra cycles of ischemia/reperfusion in experimental diabetes (Table [3](#T3){ref-type="table"}). Tsang et al. \[[@B48]\] reported that one, two and three cycles of ischemic PC significantly reduced infarct size in normal rats; however, three cycles of ischemic PC were required to limit infarct size in diabetic Goto-Kakizaki rats. Their findings suggested that the threshold for PC protection is increased in the diabetic myocardium. Liu et al. \[[@B49]\] were the first to examine the effects of DM on PC and they reported preservation of PC protection in STZ-induced DM. However, since they used a PC protocol with multiple cycles of ischemia/reperfusion only, the change in the threshold for inducing PC protection might have been missed in their study. In fact, impairment of PC by DM has been observed in multiple species (rats, rabbits and dogs) and different models of DM (STZ-induced type 1 DM and genetic models of type 2 DM) \[[@B30],[@B37],[@B50]-[@B54]\]. Mimetics of ischemic PC and PostC (diazoxide, erythropoietin, \[D-Ala^2^, D-Leu^5^-enkephalin acetate \[DADLE\] and isoflurane) were also ineffective for limitation of infarct size in DM hearts \[[@B33],[@B34],[@B37],[@B55]-[@B59]\], confirming that DM impairs intracellular signaling mechanisms relevant to myocardial protection.

Several steps in cytoprotective signaling have been found to be disrupted by DM in the heart. Blocked or attenuated signaling via phosphoinsitide-3 kinase (PI3K)-Akt, extracellular signal-regulated kinase (ERK) and/or signal transducer and activator of transcription-3 (STAT3) pathways was detected in association with loss or reduced efficiency of PC in protection against infarction \[[@B31],[@B33],[@B34],[@B36],[@B48],[@B57]-[@B59]\]. Our recent studies have shown that phosphorylation of Jak2, being upstream of PI3K-Akt signaling, is inhibited by enhanced calcineurin activity and that phosphorylation of GSK-3β by ERK is lost by an endoplasmic reticulum stress-dependent mechanism in OLETF, a rat model of obese type 2 DM \[[@B33],[@B34]\]. Furthermore, protein level of active GSK-3β, a pro-necrotic and pro-apoptotic kinase, was increased in mitochondria, leading to reduction in the threshold for mPTP opening in response to Ca^2+^ overload \[[@B34]\]. On the other hand, a protective mechanism downstream of GSK-3β phosphorylation appears to be intact in diabetic hearts, since direct pharmacological inhibitors of GSK-3β limited infarct size in diabetic hearts as in non-diabetic animals \[[@B33],[@B34],[@B54],[@B57],[@B58]\].

An important and clinically relevant issue is whether hyperglycemia per se is responsible for disruption of protective signaling in PC and PostC. Acute hyperglycemia induced by dextrose infusion attenuated infarct size limitation by ischemic PC, a mitochondrial ATP-sensitive K^+^ channel (K~ATP~ channel) opener and anesthetic agents (Table [4](#T4){ref-type="table"}). These results indicate a primary role of hyperglycemia in impairment of protective signaling. Interestingly, Przyklenk et al. \[[@B31]\] reported that the cardioprotective effect of ischemic PostC was re-established in STZ-induced diabetic mice by pancreas islet cell transplantation. Transplantation of islet cells in diabetic mice normalized both blood glucose level and free fatty acid level and cellular signaling, such as ERK phosphorylation, activated by ischemic PostC. Since dyslipidemia was also shown to attenuate the infarct size-limiting effect of ischemic PC \[[@B60],[@B61]\], restoration of myocardial response to PostC in the diabetic heart by islet cell transplantation might be achieved by normalization of both plasma glucose level and lipid profile. Nevertheless, circumstantial evidence in animal experiments supports the notion that normalization of the metabolic profile restores protective signaling mechanisms in the DM heart.

Clinical studies on PC
----------------------

PC protection in human hearts has been demonstrated by results of in vitro experiments using human ventricular myocytes \[[@B62]\] and atrial trabeculae \[[@B63]\] and by detailed analyses of myocardial responses in patients with naturally occurring ischemic syndromes \[[@B64],[@B65]\]. Since ischemic PC and PC-like phenomena in human hearts have been recently reviewed elsewhere \[[@B7],[@B65]\], we briefly summarize the results that are relevant to the effects of DM on ischemic PC. As for PC-like effects of preinfarct angina, different groups reported that pre-infarct angina was associated with smaller infarct size determined by creatine kinase (CK) release, improved left ventricular function and reduced mortality \[[@B64],[@B66]\]. Furthermore, in overall analysis of AMI patients, angina before AMI was associated with better long-term prognosis \[[@B67],[@B68]\]. However, in patients with DM, beneficial effects of pre-infarct angina were not detected \[[@B69]\]. Ishihara et al. \[[@B69]\] showed that CK release and recovery of cardiac function and in-hospital mortality after AMI were similar in DM patients with and without pre-infarct angina. DM-induced impairment of ischemic PC protection in human hearts has also been indicated by studies in which myocardial injury was assessed during angioplasty \[[@B70]\] and during a treadmill exercise test \[[@B71]\] by use of electrocardiography.

Direct evidence for diabetes-induced loss of ischemic PC protection in the human myocardium was provided by an in vitro experiment using atrial trabeculae obtained at open heart surgery. CK release and contractile dysfunction after hypoxia/reoxygenation in vitro was significantly suppressed by PC in trabeculae from non-diabetic patients but not in trabeculae from diabetic patients \[[@B63],[@B72]\].

Clinical studies on PostC
-------------------------

In contrast to PC, PostC or administration of its mimetic at the time of reperfusion is clinically feasible. In 2005, Staat et al. \[[@B73]\] translated for the first time the concept of ischemic PostC into the clinical setting. PostC with four cycles of 1-min inflation and 1-min deflation before full reperfusion successfully reduced CK release in a small and selected cohort of patients with AMI. Efficacy of ischemic PostC in patients with AMI was subsequently confirmed in a number of small-scale studies, using as endpoints cardiac biomarkers, ECG ST-segment resolution, and anatomic infarct size (Table [5](#T5){ref-type="table"}). However, three recent studies failed to show protection by ischemic PostC in terms of CK and troponin release, LV function or infarct size that was determined by delayed enhancement magnetic resonance imaging (MRI) \[[@B74]-[@B76]\]. The reasons for the discrepant results remain uncertain, but there are some possibilities: differences in the protocols of ischemic PostC, presence of co-morbidities and use of different pharmacological agents for the co-morbidities.

In the PostC protocol, duration from reperfusion to the first re-occlusion and number of re-occlusions have been shown to influence the infarct size-limiting effects of PostC in animal models of AMI \[[@B77]-[@B79]\]. Retrospective analyses by Darling et al. \[[@B80]\] and Wang et al. \[[@B81]\] suggest that larger numbers of balloon inflations--deflations were associated with greater protection in patients with AMI. However, an appropriate algorithm of PostC stimulus to maximally protect the human myocardium has not been established. In addition, protection by PostC in animal models of AMI is attenuated with aging and presence of co-morbidities, such as DM, hypertension and hypercholesterolemia \[[@B6],[@B11]\]. Although characteristics of patients, such as age and prevalence of DM, seem to be similar in the human studies (Table [5](#T5){ref-type="table"}), difference in durations of the co-morbidities might have been involved in the different outcomes. Nevertheless, the effect of DM on protection afforded by PostC has not been specifically examined in clinical studies.

The effects of pharmacological PostC (i.e., administration of pharmacological agents at reperfusion) on myocardial injury have been examined in a number of clinical trials. Results of the trials are a mixture of positive and negative results, and the reason for the discrepancy remains unknown \[[@B82]-[@B92]\]. Adenosine infusion limited infarct size, but neither the death rate during 6-month follow-up nor the rate of re-hospitalization for heart failure were reduced by the adenosine treatment \[[@B82],[@B84]\]. A *post hoc* analysis suggested that only patients with early reperfusion therapy received clinical benefits of adenosine, such as a reduction in death or heart failure \[[@B85]\]. In the J-WIND trial \[[@B86]\], the effects of nicorandil and ANP on infarct size in different study arms were examined. Administration of nicorandil failed to significantly limit infarct size, though recombinant ANP infusion was shown to induce a small but significant reduction in infarct size. The results of studies on the effect of erythropoietin administered at reperfusion were discrepant \[[@B87]-[@B92]\]. Taken together, there are a few promising agent for infarct size limitation in AMI patients, but none of their effects has been unequivocally demonstrated to be sufficient for improving prognosis.

Effects of anti-diabetic medications on AMI in diabetic patients
================================================================

Possible adverse effects of sulfonylureas on cardiac events in DM patients have been debated for decades, and recent studies have indicated that cardiovascular risk was significantly higher in DM patients treated with sulfonylureas than in those who received metformin monotherapy \[[@B93],[@B94]\]. Sulphonylureas have been shown to inhibit protection of PC and PostC by blocking the ATP-sensitive K^+^ channel (K~ATP~ channel) in cardiomyocytes, raising concern that such actions of sulphonylureas may be detrimental at the time of AMI in DM patients. However, the effects on PC and PostC are actually not uniform across sulfonylureas. Glibenclamide, a non-specific blocker of the K~ATP~ channel, abrogated the infarct size-limiting effect of PC and PostC in non-diabetic animals \[[@B6],[@B7],[@B95]\]. In contrast, glimepiride, a second-generation sulfonylurea, did not block the protective effect of PC in the animal myocardium or human myocardium \[[@B96],[@B97]\], presumably because this agent has few cardiac actions \[[@B98]\]. In addition, glimepiride was shown to have a PostC-mimetic action by activation of PI3K/Akt in the rabbit myocardium \[[@B99]\]. However, the effects of sulfonylureas on PC in diabetes have been tested in only a few studies \[[@B51],[@B96]\], since PC and PostC failed to limit infarction in most of the DM models. Interestingly, Nieszner et al. \[[@B51]\] reported that infarct-sparing effect of PC in alloxan-treated diabetic rabbits was restored by pretreatment with a low dose, but not a high dose, of glibenclamide. The mechanism by which glibenclamide restored myocardial response to PC in the DM rabbit is unclear. However, beneficial effects of glycemic control, possibly on PI3K/Akt signaling, might have overwhelmed the effect of partial inhibition of cardiac K~ATP~ channels when an appropriate dose of glibenclamide was selected.

Metformin is an insulin-sensitizing agent that reduces hepatic glucose output and increases the uptake of glucose in peripheral tissues, including the skeletal muscle. In non-diabetic animals, metformin reduced infarct size by activation of AMP-activated protein kinase and/or Akt \[[@B95]\]. However, whether metformin is additive to ischemic PC or PostC has not been examined. Infarct size-limiting effect of metformin in diabetic animals was controversial: there are two positive reports \[[@B40],[@B100]\] and one negative report \[[@B101]\].

Thiazolidinediones (pioglitazone, rosiglitazone) administered before ischemia reduced infarct size in both normal and diabetic animals \[[@B39],[@B41],[@B95]\]. However, the impact of the cardioprotective effect of thiazolidinediones on clinical outcome is unclear, since the effects of pioglitazone and rosiglitazone on risk of cardiovascular events appear discrepant \[[@B102]\].

In the past few years, growing evidence has demonstrated cardiovascular effects of incretin-based therapy using glucagon-like peptide-1 (GLP-1) receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-4) \[[@B95],[@B103]-[@B105]\]. However, the effects of GLP-1 receptor agonists or DPP-4 inhibitors on ischemia/reperfusion injury have not been examined in diabetic animals except for a study by Huisamen et al. \[[@B106]\] They reported that enlargement of infarct size in obese pre-diabetic rats was reduced by treatment with a DPP-4 inhibitor for 4 weeks \[[@B106]\]. Further investigation is necessary for clarifying the effects of GLP-1 analogues and DPP-4 inhibitors on intracellular protective signaling and its modification by DM, though there are a number of on-going large-scale clinical trials to test the effects of incretin-based therapy on cardiovascular outcomes \[[@B107]\].

Conclusions and perspectives
============================

DM potentially increases myocardial susceptibility to ischemia/reperfusion injury, though it cannot be explained by chronic hyperglycemia alone. DM also modifies myocardial responses to ischemic and pharmacological PC and PostC by disruption of intracellular signaling responsible for enhancement of resistance to cell death. These alterations in the diabetic heart appear to underlie the poor prognosis of DM patients after AMI. In addition, a defect of the protective mechanisms caused by aging, DM and possibly other co-morbidities is one of possible reasons why infarct size-limiting effects of agents in animal studies could not have been translated into AMI patients.

Analyses of modifications of cytoprotective signaling by DM, heart failure, dyslipidemia and hypertension generally showed that defects in the signaling by the pathological factors are upstream of a step of GSK-3β phosphorylation and mPTP regulation \[[@B6],[@B9]\]. Hence, a reasonable approach to protect the heart in DM patients is manipulation of protective mechanisms at the level of GSK-3β or mPTP. Blockade of mPTP opening by cyclosporine A at the time of reperfusion is one such approach, and its effect was first examined in 58 AMI patients \[[@B108]\]. Infarct size determined by MRI at 5 days after AMI was significantly limited by cyclosporine A and the beneficial effects persisted until 6 month after AMI \[[@B109]\]. The results are very promising and support the feasibility of a strategy for cardioprotection targeting the mPTP. However, how DM modifies the mPTP regulation and how we can suppress opening of the mPTP at the time of reperfusion need to be further investigated for devising a novel therapy for cardioprotection in DM patients.
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